Shopping Cart
- Remove All
Your shopping cart is currently empty
Darovasertib
Catalog No. T5600Cas No. 1874276-76-2
Alias LXS196
Darovasertib (LXS196) is a potent, selective, and orally active protein kinase C (PKC) inhibitor with IC50 values of 1.9 nM for PKCα, 0.4 nM for PKCθ, and 3.1 μM for GSK3β.
Darovasertib
Catalog No. T5600Alias LXS196Cas No. 1874276-76-2
Darovasertib (LXS196) is a potent, selective, and orally active protein kinase C (PKC) inhibitor with IC50 values of 1.9 nM for PKCα, 0.4 nM for PKCθ, and 3.1 μM for GSK3β.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $48 | In Stock | |
| 5 mg | $138 | In Stock | |
| 10 mg | $198 | In Stock | |
| 25 mg | $369 | In Stock | |
| 50 mg | $549 | In Stock | |
| 100 mg | $789 | In Stock | |
| 500 mg | $1,630 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $162 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Darovasertib"
α-Vitamin E
Cited
Vitamin E, D-α-Tocopherol, Dexrabeprazole Sodium, Alpha-Tocopherol, 5,7,8-Trimethyltocol, (+)-alpha-Tocopherol
T164859-02-9
α-Vitamin E (Dexrabeprazole Sodium) is a naturally-occurring form of vitamin E, a fat-soluble vitamin with potent antioxidant properties.
- $38
Size
QTY
CitedStaurosporine
Cited
CGP 41251, Antibiotic AM-2282, AM-2282
T668062996-74-1
Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6/15/2/3/3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.
- $56
Size
QTY
CitedMitoxantrone dihydrochloride
NSC-301739, mitozantrone dihydrochloride, Mitoxantrone hydrochloride, Mitoxantrone 2HCl
T015870476-82-3
Mitoxantrone dihydrochloride (NSC-301739) is the hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. It is a type II topoisomerase inhibitor.
- $50
Size
QTY
R59949
Cited
R-59949, R 59949
T26019120166-69-0
R59949 is used as a Diacylglycerol kinase (DGK) inhibitor.
- $39
Size
QTY
CitedN-Desmethyltamoxifen hydrochloride
T1214815917-65-4
N-Desmethyltamoxifen hydrochloride is the primary metabolite of tamoxifen in humans.
- $35
Size
QTY
Ellagic acid Cited
Gallogen, Elagostasine
T0465476-66-4
Ellagic acid (Gallogen), a thickened tetracyclic natural product, is a potent CK2 inhibitor (IC50=40 nM; Ki=20 nM) with ATP-competitive properties. Ellagic acid is an antioxidant and also possesses antiproliferative activity.
Carbonic AnhydraseCasein KinaseEndogenous MetaboliteHedgehog/SmoothenedPKAPKCReactive Oxygen SpeciesSykTopoisomerase
- $44
Size
QTY
CitedFasudil hydrochloride Cited
HA-1077 hydrochloride, HA-1077, Fasudil HCl, Fasudil (HA-1077) HCl, AT-877
T3060105628-07-7
Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
- $35
Size
QTY
CitedMethyl-Hesperidin
T022811013-97-1
Methyl Hesperidin, a flavanone glycoside (flavonoid) (C28H34O15), is abundant in citrus fruits. Its aglycone form is called hesperetin.
- $50
Size
QTY
DCPLA-ME
Methyl 8-[2-[(2-pentylcyclopropyl)methyl]cyclopropyl]octanoate, Methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate, DCPLA methyl ester, 2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoic acid methyl ester
T1098056687-67-3In house
DCPLA-ME (2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoic acid methyl ester) is the methyl ester form of DCPLA and can be used to treat neurodegenerative diseases. It is an effective PKCε activator.
- $79
Size
QTY
Myricitrin Cited
Myricitrine, Myricetrin
T275717912-87-7
Myricitrin (Myricitrine), a flavonoid compound isolated from the root bark of Myrica cerifera, exerts antinociceptive effects.
- $50
Size
QTY
CitedMidostaurin
PKC412, N-Benzoylstaurosporine, CGP41231, CGP 41251
T3211120685-11-2
PKC412(Midostaurin (PKC412); CGP41231; CGP41251) is a broad spectrum protein kinase inhibitor. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.
- $47
Size
QTY
Select Batch
Purity:99.67%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Darovasertib (LXS196) is a potent, selective, and orally active protein kinase C (PKC) inhibitor with IC50 values of 1.9 nM for PKCα, 0.4 nM for PKCθ, and 3.1 μM for GSK3β. |
| Targets&IC50 | PKCθ:0.4 nM , PKCα:1.9 nM , GSK-3β:3.1 μM |
| In vitro | An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, protein kinase C inhibitor Darovasertib binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival. |
| Alias | LXS196 |
| Molecular Weight | 472.47 |
| Formula | C22H23F3N8O |
| Cas No. | 1874276-76-2 |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (211.65 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Darovasertib | purchase Darovasertib | Darovasertib cost | order Darovasertib | Darovasertib chemical structure | Darovasertib in vitro | Darovasertib formula | Darovasertib molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.